DePuy Synthes Announces CE Mark for BI-MENTUM Dual Mobility Hip

DePuy Synthes has been informed of CE Mark approval for the BI-MENTUM™ Dual Mobility hip for patients with a higher risk of dislocation. In addition to the burden of repeat surgeries, surgical treatment of a dislocating total hip can reportedly raise the cost of hip replacement by 342%.

BI-MENTUM features a standard femoral head articulating within a large polyethylene liner which swivels within a metal shell. Currently available in the U.S., BI-MENTUM is slated to enter European markets in April 2020. The system complements other hip stems with highly polished necks, including the company’s CORAIL® Hip System that has more than 2.5 million implantations to date.

In 2018, the company entered into a distribution agreement with SERF and is now bringing dual-mobility acetabular cups, identical to Serf® dual-mobility cups, under its own BI-MENTUM brand name. This technology has a track record of 100% cup survivorship at 10 years, and an implant milestone of 165,000 cups since 2007.

“With an increasing number of patients undergoing hip replacement surgery, surgeons need to address a broader range of surgical needs to help their patients stay active and get on with their lives. Securing the CE Mark on BI-MENTUM enables us to better serve our customers and patients across Europe with a solution that is designed to make a continued difference in hip replacement,” said Aaron Villaruz, Vice President and Global Platform Leader for Hips at DePuy Synthes.

JAV

Julie A. Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

RELATED ARTICLES



CONTACT BONEZONE

 

CONTACT BONEZONE